United Therapeutics (UTHR) EBIT Margin (2009 - 2026)

United Therapeutics has disclosed EBIT Margin across 18 years of filings, most recently posting 41.69% for Q1 2026.

• EBIT Margin for Q1 2026 came in at 41.69%, down 650.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 45.29% (down 159.0% YoY), and the FY2025 annual result was 46.89%, down 96.0% from the prior year.
• EBIT Margin came in at 41.69% for Q1 2026 at United Therapeutics, down from 45.14% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 62.35% in Q1 2022 to a low of 35.73% in Q4 2022.
• The 5-year median for EBIT Margin is 48.19% (2025), against an average of 48.7%.
• Across the five-year window, EBIT Margin surged 7944 bps in 2022 and sank 785 bps in 2024, its largest moves.
• United Therapeutics' EBIT Margin stood at 35.73% in 2022, then grew by 18 bps to 42.31% in 2023, then increased by 15 bps to 48.61% in 2024, then fell by 7 bps to 45.14% in 2025, then decreased by 8 bps to 41.69% in 2026.
• The last three EBIT Margin figures came in at 41.69% (Q1 2026), 45.14% (Q4 2025), and 48.59% (Q3 2025), per Business Quant data.